Differences in incidence and co-occurrence of vaccine and nonvaccine human papillomavirus types in Finnish population before human papillomavirus mass vaccination suggest competitive advantage for HPV33

International Journal of Cancer

Volumn 128, Issue 5, 2011, Pages 1114-1119

  Merikukka, Marko ^a   Kaasila, Marjo ^a   Namujju, Proscovia B ^a   Palmroth, Johanna ^b   Kirnbauer, Reinhard ^c   Paavonen, Jorma ^d   Lehtinen, Matti ^a,e  

^a NATIONAL PUBLIC HEALTH INSTITUTE   (Finland)

^b KUOPIO UNIVERSITY HOSPITAL   (Finland)

^c Universitatsklinik fur Dermatologie   (Austria)

^d UNIVERSITY OF HELSINKI   (Finland)

^e UNIVERSITY OF TAMPERE   (Finland)

Author keywords

competition; human papillomavirus; incidence rate ratio; population; serology

Indexed keywords

VIRUS ANTIBODY; WART VIRUS VACCINE;

ADULT; AGE DISTRIBUTION; ANTIBODY DETECTION; ANTIBODY TITER; ARTICLE; CONTROLLED STUDY; FEMALE; FINLAND; FIRST TRIMESTER PREGNANCY; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; HUMAN PAPILLOMAVIRUS TYPE 33; INCIDENCE; MAJOR CLINICAL STUDY; MASS IMMUNIZATION; PAPILLOMAVIRUS INFECTION; POPULATION RESEARCH; PRIORITY JOURNAL; RISK ASSESSMENT; SEROCONVERSION; SEROLOGY;

ALPHAPAPILLOMAVIRUS; ANTIBODIES, VIRAL; COHORT STUDIES; FEMALE; FINLAND; HUMANS; PREGNANCY; VIRAL VACCINES;

EID: 78650739541     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.25675     Document Type: Article

References (28)

1. Clifford GM, Smith JS, Plummer M, Muñoz N, Franceschi S,. Human papilloma virus types in invasive cervical cancer worldwide: a meta-analysis. Br J Cancer 2003; 88: 63-73.
2. Barnabas R, Laukkanen P, Koskela P, Kontula O, Lehtinen M, Garnett G,. Epidemiology of HPV 16 and cervical cancer in Finland and the potential impact of vaccination: mathematical modelling analyses. PLoS Med 2006; 3: e138.
3. Laukkanen P, Koskela P, Pukkala E, Dillner J, Läärä E, Knekt P, Lehtinen M,. Time trends in incidence and prevalence of human papillomavirus type 6, 11 and 16 infections in Finland. J Gen Virol 2003; 84: 2105-9.
4. Lehtinen M, Kaasila M, Pasanen K, Patama T, Palmroth J, Laukkanen P, Pukkala E, Koskela P,. Seroprevalence atlas of infections with oncogenic and non-oncogenic human papillomaviruses in Finland in the 1980's and 1990's. Int J Cancer 2006; 119: 2612-9.
5. Kaasila M, Koskela P, Kirnbauer R, Pukkala E, Surcel HM, Lehtinen M,. Population dynamics of serologically identified coinfections with human papillomavirus types 11, 16, 18 and 31 in fertile-aged Finnish women. Int J Cancer 2009; 125: 2166-72.
6. Thomas KK, Hughes JP, Kuypers JM, Kiviat NB, Lee SK, Adam DE, Koutsky LA,. Concurrent and sequential acquisition of different genital human papillomavirus types. J Infect Dis 2000; 182: 1097-102.
7. Palmroth J, Namujju P, Simen-Kapeu A, Kataja V, Surcel HM, Tuppurainen M, Yliskoski M, Syrjänen K, Lehtinen M,. Natural seroconversion to high-risk human papillomaviruses is not protective against related HPV genotypes. Scand J Infect Dis 2010; 42: 379-84.
8. Banura C, Franceschi S, van Doorn LJ, Arslan A, Kleter B, Wabwire-Mangen F, Mbidde EK, Quint W, Weiderpass E,. Prevalence, incidence and clearance of human papillomavirus infection among young primiparous pregnant women in Kampala, Uganda. Int J Cancer 2008; 123: 2180-7.
9. Watt A, Garwood D, Jackson M, Younger N, Ragin C, Smikle M, Fletcher H, McFarlane-Anderson N,. High-risk and multiple human papillomavirus (HPV) infections in cancer-free Jamaican women. Infect Agent Cancer 2009; 4: S11.
10. Trottier H, Mahmud S, Costa MC, Sobrinho JP, Duarte-Franco E, Rohan TE, Ferenczy A, Villa LL, Franco EL,. Human papillomavirus infections with multiple types and risk of cervical neoplasia. Cancer Epidemiol Biomarkers Prev 2006; 15: 1274-80.
11. Markowitz, L, Dunne EF, Saraiya M, Lawson H, Chesson H, Unger ER,. Quadrivalent human papillomavirus vaccine. Recommendations of the Advisory Committee on immunization practices. MMWR 2007; 56: 1-24.
12. FDA, approves new vaccine for prevention of cervical cancer, 2009. Accessed March 11, 2010.
13. EMA, (EPAR), Gradasil, 2006. Accessed March 11, 2010.
14. EMA, (EPAR), Cervarix, 2007. Accessed March 11, 2010.
15. Brown DR, Krüger Kjaer S, Sigurdsson K, Iversen O-E, Hernandez-Avila M, Wheeler CM, Perez G, Koutsky LA, Tay EH, Garcia P, Ault KA, Garland S,. The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16 and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in generally HPV-naive women aged 16-26 Years. J Infect Dis 2009; 199: 926-35.
16. Harper DM, Franco EL, Wheeler CM, Moscicki AB, Romanowski B, Roteli-Martins CM, Jenkins D, Schuind A, Costa Clemens SA, Dubin G,; HPV Vaccine Study group. Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial. Lancet 2006; 367: 1247-55.
17. Paavonen J, Naud P, Salmerõn J, Wheeler CM, Chow SN, Apter D, Kitchener H, Castellsague X, Teixeira JC, Skinner SR, Hedrick J, Jaisamrarn U, et al. Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV-types (PATRICIA): final analysis of a double-blind, randomized study in young women. Lancet 2009; 374: 301-14.
18. Lehtinen M, Paavonen J,. Vaccination against human papillomaviruses shows great promise. Lancet 2004; 364: 1731-2.
19. Huamn SS, Hinrichsen VL, Stevenson AE, Rifas-Shiman SL, Kleinman K, Pelton SI, Lipsitch M, Hanage WP, Lee GM, Finkelstein JA,. Continued impact of pneumococcal conjugate vaccine on carriage in young children. Pediatrics 2009; 124: e1-11.
20. Collins S, Mazloomzadeh S, Winter H, Blomfield P, Bailey A, Young LS, Woodman Ciaran BJ,. High incidence of cervical human papilloma virus infection in women during their first sexual relationship. BJOG 2002; 109: 96-8.
21. Dillner J, Kallings I, Brihmer C, Sikström B, Koskela P, Lehtinen M, Schiller JT, Sapp M, MÃrdh PA,. Seropositivities to human papillomavirus types 16, 18, or 33 capsids and to Chlamydia trachomatis are markers of sexual behavior. J Infect Dis 1996; 173: 1394-8.
22. Paavonen J, Halttunen M, Hansson B-G, Nieminen P, Rostila T, Lehtinen M,. Feasibility studies on HPV vaccination. J Clin Virol 2000; 19: 25-30.
23. Auvinen E, Niemi M, Malm Christian, Zilliacus R, Trontti A, Fingerroos R, Lehtinen M, Paavonen J,. High prevalence of HPV among female students in Finland. Scand J Infect Dis 2005; 37: 873-6.
24. Kjellberg L, Wang Z, Wiklund F, Edlund K, Angström T, Lenner P, Sjöberg I, Hallmans G, Wallin KL, Sapp M, Schiller J, Wadell G, Mählck CG, Dillner J,. Sexual behaviour and papillomavirus exposure in cervical intraepithelial neoplasia: a population-based case-control study. J Gen Virol 1999; 80: 391-8.
25. af Geijersstam V, Kibur M, Wang Z, Koskela P, Pukkala E, Schiller J, Lehtinen M, Dillner J,. Stability over time of serum antibody levels to human papillomavirus type 16. J Infect Dis 1998; 177: 1710-4.
26. Ferguson M, Heath A, Johnes S, Pagliusi S, Dillner J,. Results of the first WHO international collaborative study on the standardization of the detection of antibodies to human papillomaviruses. Int J Cancer 2006; 118: 1508-14.
27. Pagliusi SR, Dillner J, Pawlita M, Quint WG, Wheeler CM, Ferguson M,. International standard reagents for harmonization of HPV serology and DNA assays-an update. Vaccine 2006; 24: S3/193-200.
28. Lehtinen M, French K, Dillner J, Paavonen J, Garnett G,. Sound implementation of HPV vaccination. Future Med 2008; 5: 289-94.